Overview

Study of Oral Fampridine-SR in Multiple Sclerosis

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.

Phase:

Phase 3

Details

Lead Sponsor:

Acorda Therapeutics

Treatments:

4-Aminopyridine